Viridian Therapeutics Sets Price for $251 Million Public Stock Offering
Public Offering Announcement: Viridian Therapeutics has priced an underwritten public offering of 11,425,000 shares of common stock at $22.00 per share, with expected gross proceeds of approximately $251.35 million.
Use of Proceeds: The funds raised will be used for commercial launch activities related to veligrotug and VRDN-003, research and development, as well as general corporate purposes.
Clinical Trials: Viridian is advancing multiple candidates for thyroid eye disease (TED), including veligrotug and VRDN-003, both of which are undergoing pivotal phase 3 clinical trials that have reported positive topline data.
Forward-Looking Statements: The press release includes forward-looking statements regarding the company's expectations and plans, which are subject to various risks and uncertainties, and should not be relied upon as guarantees of future performance.
Trade with 70% Backtested Accuracy
Analyst Views on VRDN
About VRDN
About the author
Biotech Stocks Surge in 2025 with $30.9 Billion M&A Wave
- M&A Surge: In 2025, small and mid-cap biopharma companies accounted for 57% of acquisitions by deal count, with 33 deals totaling $30.9 billion, indicating a significant recovery in market confidence despite a drop in median deal value from $516 million to $303 million.
- Shift in Investor Focus: Investor attention has shifted from GLP-1 obesity drugs to cancer and autoimmune disease treatments in 2025, particularly next-generation cell therapies, reflecting strong demand for innovative treatment options and potential growth opportunities in the biotech sector.
- Strong Clinical Data: Approximately $6 billion in acquisitions related to next-generation cell therapies occurred over the past six months, highlighting significant interest from big pharma in this niche, which could drive stock price increases for involved companies.
- Optimistic Outlook: Analysts expect increased M&A and strategic partnerships in 2026, particularly in immunology and rare diseases, with a lower interest rate environment improving funding conditions and further supporting the growth of biotech companies.
Viridian Therapeutics (VRDN) Secures FDA Priority Review for Veligrotug in Thyroid Eye Disease
- FDA Priority Review: Viridian Therapeutics' Biologics License Application for Veligrotug has been accepted for priority review by the FDA, with a decision expected by June 30, 2026, which will expedite its entry into the thyroid eye disease treatment market to meet growing patient needs.
- Clinical Trial Success: Veligrotug met all primary and secondary endpoints in the THRIVE and THRIVE 2 phase 3 clinical trials, demonstrating significant improvement in chronic thyroid eye disease patients' diplopia symptoms, with rapid clinical benefits enhancing its market competitiveness.
- Breakthrough Therapy Designation: In May 2025, the FDA granted Veligrotug breakthrough therapy designation, indicating its potential in treating thyroid eye disease, which further elevates investor and market interest in the drug.
- European Market Plans: Viridian plans to submit a Marketing Authorisation Application to the European Medicines Agency in the first quarter of 2026, reflecting its strategic intent for global expansion and aiming to capture growth opportunities in international markets.
Argenx Suspends Phase 3 Trial for Thyroid Eye Disease, Opening Opportunities for Competitors Like Viridian Therapeutics
Discontinuation of Phase 3 Studies: Argenx SE has decided to halt the Phase 3 UplighTED studies of efgartigimod for moderate to severe thyroid eye disease after an Independent Data Monitoring Committee recommended stopping the trials for futility based on interim analysis data.
Safety Profile: Despite the discontinuation, efgartigimod demonstrated a favorable safety and tolerability profile, with no new safety signals identified during the trials.
Future Data Analysis: Following the closure of the studies, Argenx plans to conduct a comprehensive analysis of the collected data, which will be shared at a future medical meeting.
Market Impact: The announcement surprised analysts, with some noting that the news could positively affect the IGF-1R antibody class, while Argenx shares fell by nearly 5% following the news.
Viridian Therapeutics Grants 171,900 Stock Options to New Employees
- Incentive Plan Approval: Viridian Therapeutics' Compensation Committee approved the grant of 171,900 non-qualified stock options to three new employees, aimed at attracting top talent and enhancing employee loyalty.
- Grant Details: The exercise price of these stock options matches the closing price on the grant date and will vest over four years, with 25% vesting after the first year and the remainder in monthly installments, ensuring employee retention.
- Compliance Assurance: This grant complies with Nasdaq Listing Rule 5635(c)(4), demonstrating the company's commitment to compliance and transparency in talent acquisition, which bolsters investor confidence.
- R&D Progress: Viridian is advancing multiple clinical candidates for thyroid eye disease, actively conducting global phase 3 trials, showcasing the company's strong growth potential in the biopharmaceutical sector.
Analyst Predicts Viridian's New Thyroid Eye Treatment May Surpass Amgen's Tepezza
William Blair Coverage Initiation: William Blair has initiated coverage on Viridian Therapeutics Inc. (NASDAQ: VRDN), highlighting the company's anti-IGF-1R franchise as a significant advancement over Amgen Inc.’s Tepezza for treating thyroid eye disease (TED).
Market Potential and Advantages: The analyst notes that while the U.S. TED market has plateaued, new therapies like veligrotug, which require fewer and shorter infusions and may have a better safety profile, could expand the market.
FDA Application and Approval Timeline: Viridian submitted a marketing application for veligrotug to the FDA, requesting Priority Review, which could lead to a potential commercial launch by mid-2026 if approved.
Future Developments: William Blair also emphasizes the potential of VRDN-003, a subcutaneously administered treatment with Phase 3 data expected in early 2026, and plans for an FDA application submission by the end of 2026.
Viridian Metals Closes First Tranche of $591,543 Private Placement
- Successful Financing: Viridian Metals successfully issued 296,672 flow-through shares and 658,999 hard dollar units in the first tranche of its private placement, raising a total of $591,543.68, reflecting strong investor demand for the company's prospects.
- Clear Fund Utilization: Proceeds from the flow-through shares will be allocated to eligible Canadian exploration expenses under the Income Tax Act, specifically targeting the development of surface geochemistry, geophysics, and drill targeting at the company's Labrador mining projects.
- Management Efficiency Improvement: The company completed a vertical short-form amalgamation with its wholly-owned subsidiary, Viridian Metals Corp., aimed at streamlining financial and regulatory reporting processes, thereby reducing administrative costs and enhancing overall operational efficiency.
- Positive Future Outlook: Viridian indicated plans for a second tranche of financing despite being well-funded, aiming to attract further investors and drive sustained growth for the company.
Biotech Stocks Surge in 2025 with $30.9 Billion M&A Wave
- M&A Surge: In 2025, small and mid-cap biopharma companies accounted for 57% of acquisitions by deal count, with 33 deals totaling $30.9 billion, indicating a significant recovery in market confidence despite a drop in median deal value from $516 million to $303 million.
- Shift in Investor Focus: Investor attention has shifted from GLP-1 obesity drugs to cancer and autoimmune disease treatments in 2025, particularly next-generation cell therapies, reflecting strong demand for innovative treatment options and potential growth opportunities in the biotech sector.
- Strong Clinical Data: Approximately $6 billion in acquisitions related to next-generation cell therapies occurred over the past six months, highlighting significant interest from big pharma in this niche, which could drive stock price increases for involved companies.
- Optimistic Outlook: Analysts expect increased M&A and strategic partnerships in 2026, particularly in immunology and rare diseases, with a lower interest rate environment improving funding conditions and further supporting the growth of biotech companies.
Viridian Therapeutics (VRDN) Secures FDA Priority Review for Veligrotug in Thyroid Eye Disease
- FDA Priority Review: Viridian Therapeutics' Biologics License Application for Veligrotug has been accepted for priority review by the FDA, with a decision expected by June 30, 2026, which will expedite its entry into the thyroid eye disease treatment market to meet growing patient needs.
- Clinical Trial Success: Veligrotug met all primary and secondary endpoints in the THRIVE and THRIVE 2 phase 3 clinical trials, demonstrating significant improvement in chronic thyroid eye disease patients' diplopia symptoms, with rapid clinical benefits enhancing its market competitiveness.
- Breakthrough Therapy Designation: In May 2025, the FDA granted Veligrotug breakthrough therapy designation, indicating its potential in treating thyroid eye disease, which further elevates investor and market interest in the drug.
- European Market Plans: Viridian plans to submit a Marketing Authorisation Application to the European Medicines Agency in the first quarter of 2026, reflecting its strategic intent for global expansion and aiming to capture growth opportunities in international markets.
Argenx Suspends Phase 3 Trial for Thyroid Eye Disease, Opening Opportunities for Competitors Like Viridian Therapeutics
Discontinuation of Phase 3 Studies: Argenx SE has decided to halt the Phase 3 UplighTED studies of efgartigimod for moderate to severe thyroid eye disease after an Independent Data Monitoring Committee recommended stopping the trials for futility based on interim analysis data.
Safety Profile: Despite the discontinuation, efgartigimod demonstrated a favorable safety and tolerability profile, with no new safety signals identified during the trials.
Future Data Analysis: Following the closure of the studies, Argenx plans to conduct a comprehensive analysis of the collected data, which will be shared at a future medical meeting.
Market Impact: The announcement surprised analysts, with some noting that the news could positively affect the IGF-1R antibody class, while Argenx shares fell by nearly 5% following the news.
Viridian Therapeutics Grants 171,900 Stock Options to New Employees
- Incentive Plan Approval: Viridian Therapeutics' Compensation Committee approved the grant of 171,900 non-qualified stock options to three new employees, aimed at attracting top talent and enhancing employee loyalty.
- Grant Details: The exercise price of these stock options matches the closing price on the grant date and will vest over four years, with 25% vesting after the first year and the remainder in monthly installments, ensuring employee retention.
- Compliance Assurance: This grant complies with Nasdaq Listing Rule 5635(c)(4), demonstrating the company's commitment to compliance and transparency in talent acquisition, which bolsters investor confidence.
- R&D Progress: Viridian is advancing multiple clinical candidates for thyroid eye disease, actively conducting global phase 3 trials, showcasing the company's strong growth potential in the biopharmaceutical sector.
Analyst Predicts Viridian's New Thyroid Eye Treatment May Surpass Amgen's Tepezza
William Blair Coverage Initiation: William Blair has initiated coverage on Viridian Therapeutics Inc. (NASDAQ: VRDN), highlighting the company's anti-IGF-1R franchise as a significant advancement over Amgen Inc.’s Tepezza for treating thyroid eye disease (TED).
Market Potential and Advantages: The analyst notes that while the U.S. TED market has plateaued, new therapies like veligrotug, which require fewer and shorter infusions and may have a better safety profile, could expand the market.
FDA Application and Approval Timeline: Viridian submitted a marketing application for veligrotug to the FDA, requesting Priority Review, which could lead to a potential commercial launch by mid-2026 if approved.
Future Developments: William Blair also emphasizes the potential of VRDN-003, a subcutaneously administered treatment with Phase 3 data expected in early 2026, and plans for an FDA application submission by the end of 2026.
Viridian Metals Closes First Tranche of $591,543 Private Placement
- Successful Financing: Viridian Metals successfully issued 296,672 flow-through shares and 658,999 hard dollar units in the first tranche of its private placement, raising a total of $591,543.68, reflecting strong investor demand for the company's prospects.
- Clear Fund Utilization: Proceeds from the flow-through shares will be allocated to eligible Canadian exploration expenses under the Income Tax Act, specifically targeting the development of surface geochemistry, geophysics, and drill targeting at the company's Labrador mining projects.
- Management Efficiency Improvement: The company completed a vertical short-form amalgamation with its wholly-owned subsidiary, Viridian Metals Corp., aimed at streamlining financial and regulatory reporting processes, thereby reducing administrative costs and enhancing overall operational efficiency.
- Positive Future Outlook: Viridian indicated plans for a second tranche of financing despite being well-funded, aiming to attract further investors and drive sustained growth for the company.
